Mineralys Therapeutics, Common Stock Net Income
| MLYS Stock | 12.49 0.62 5.22% |
Mineralys Therapeutics, Common fundamentals help investors to digest information that contributes to Mineralys Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Mineralys Stock. The fundamental analysis module provides a way to measure Mineralys Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mineralys Therapeutics, stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -56.6 M | -53.8 M | |
| Net Loss | -26.8 M | -28.2 M | |
| Net Loss | -71.9 M | -68.3 M | |
| Net Loss | (1.99) | (1.89) |
Mineralys | Net Income |
Mineralys Therapeutics, Common Company Net Income Analysis
Mineralys Therapeutics,'s Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Mineralys Therapeutics, Net Income | (71.9 M) |
Most of Mineralys Therapeutics,'s fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mineralys Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Mineralys Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Mineralys Therapeutics, Common reported net income of (71.9 Million). This is 121.07% lower than that of the Biotechnology sector and 202.64% lower than that of the Health Care industry. The net income for all United States stocks is 112.59% higher than that of the company.
Mineralys Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mineralys Therapeutics,'s direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mineralys Therapeutics, could also be used in its relative valuation, which is a method of valuing Mineralys Therapeutics, by comparing valuation metrics of similar companies.Mineralys Therapeutics, is currently under evaluation in net income category among its peers.
Mineralys Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mineralys Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mineralys Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Mineralys Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | 624.7 M | ||||
| Shares Outstanding | 49.77 M | ||||
| Shares Owned By Insiders | 2.60 % | ||||
| Shares Owned By Institutions | 97.40 % | ||||
| Number Of Shares Shorted | 1.39 M | ||||
| Price To Book | 2.62 X | ||||
| EBITDA | (84.66 M) | ||||
| Net Income | (71.9 M) | ||||
| Total Debt | 10.48 M | ||||
| Book Value Per Share | 4.76 X | ||||
| Cash Flow From Operations | (81.17 M) | ||||
| Short Ratio | 10.39 X | ||||
| Earnings Per Share | (3.31) X | ||||
| Target Price | 32.57 | ||||
| Number Of Employees | 28 | ||||
| Market Capitalization | 621.61 M | ||||
| Total Asset | 251.64 M | ||||
| Retained Earnings | (124.71 M) | ||||
| Working Capital | 238.62 M | ||||
| Net Asset | 251.64 M |
About Mineralys Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mineralys Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mineralys Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mineralys Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.